Form 4: Blueprint Medicines Executive Sells Shares to Cover Tax Obligations
SEC Form 4 Filing
Fouad Namouni, President of R&D at Blueprint Medicines, sold shares to cover tax withholding obligations related to vesting restricted stock units.
Summary
- On March 5, 2025, Fouad Namouni, President of R&D at Blueprint Medicines Corp, sold 6,489 shares of common stock at a price of $88.8 per share.
- The sale was executed to cover tax withholding obligations associated with the vesting of restricted stock units.
- Following the transaction, Namouni directly owns 75,781 shares of Blueprint Medicines Corp.
- The sale was not a discretionary trade but an automatic 'sell to cover' transaction to satisfy tax obligations.
Sentiment
Score: 5
Explanation: The document is a routine regulatory filing detailing a stock sale for tax purposes, which is neither particularly positive nor negative.
Industry Context
Form 4 filings are standard disclosures required by the SEC when company insiders (officers, directors, or those holding 10% or more of the company's shares) buy or sell the company's securities. This provides transparency to the market regarding insider transactions.
Stakeholder Impact
- The transaction has a minimal impact on stakeholders as it is a routine sale to cover tax obligations.
Key Dates
| Date | Description |
|---|---|
| 03/05/2025 | Date of stock sale transaction. |
| 03/06/2025 | Date of signature on the Form 4 filing. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.